It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Protection from viral infections depends on immunoglobulin isotype switching, which endows antibodies with effector functions. Here, we find that the protein kinase DYRK1A is essential for B cell-mediated protection from viral infection and effective vaccination through regulation of class switch recombination (CSR). Dyrk1a-deficient B cells are impaired in CSR activity in vivo and in vitro. Phosphoproteomic screens and kinase-activity assays identify MSH6, a DNA mismatch repair protein, as a direct substrate for DYRK1A, and deletion of a single phosphorylation site impaired CSR. After CSR and germinal center (GC) seeding, DYRK1A is required for attenuation of B cell proliferation. These findings demonstrate DYRK1A-mediated biological mechanisms of B cell immune responses that may be used for therapeutic manipulation in antibody-mediated autoimmunity.
Class switch recombination (CSR) is a process by which B cells switch their immunoglobulin isotype and develop pathogen-eliminating antibodies. Here, the authors show that a protein kinase DYRK1A is required for protection from viral infection through the regulation of CSR and effective clonal expansion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Weizmann Institute of Science, Department of Systems Immunology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
2 St. Jude Children’s Research Hospital, Department of Hematology, Memphis, USA (GRID:grid.240871.8) (ISNI:0000 0001 0224 711X)
3 Bar Ilan University, Faculty of Engineering, Ramat Gan, Israel (GRID:grid.22098.31) (ISNI:0000 0004 1937 0503)
4 Vita-Salute San Raffaele University and Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
5 Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, De Botton Institute for Proteomics, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
6 Vita-Salute San Raffaele University and Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884); IRCCS San Raffaele Scientific Institute, Experimental Imaging Center, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)